{
  "docId": "019de072-a701-779d-b9c1-29622b36dd41",
  "docSlug": "f2c95dae10c304072442cd11deed84ec",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 53 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 12,
  "pageCount": 53,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": "Includes a line chart for Xifaxan NRx growth and two metric boxes for revenue performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-a701-779d-b9c1-29622b36dd41/12",
  "deckHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41",
  "deckJsonHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41.json",
  "deckAnchorHref": "/decks/019de072-a701-779d-b9c1-29622b36dd41#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.56,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Xifaxan NRx Growth Trend - Primary Care",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "748a33af-60cf-43e7-8aad-ecd1e239180b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.15,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": "Xifaxan, Trulance, Relistor logos",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bea4c811-bdae-4819-b8f8-6252c8cbdfd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.23,
        "y": 0.16
      },
      "kind": "list",
      "text": "Revenue growth of 1%; Headwind due to non-recurrence of 1Q21 wholesaler inventory build of ~$50 million; PCP shifting focus to treating COVID-19; Xifaxan market share increased; Increasing omni-channel marketing; IBS-D Volume Growth: +3% vs. 1Q21",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c121e773-fe1f-4d8e-8d87-d6d5be07020d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.23,
        "y": 0.6
      },
      "kind": "list",
      "text": "Reported revenue growth of 14%; TRx volume growth of 14%; Outpaced market growth which increased by 6%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea99fd8c-c870-463e-9e84-e095bf5525ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.28,
        "x": 0.23,
        "y": 0.79
      },
      "kind": "list",
      "text": "Flat reported growth, with Relistor oral TRx volume growth of 14%",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5a31560-695b-463e-86e0-e19f05e8f226",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.38,
        "x": 0.56,
        "y": 0.76
      },
      "kind": "metric",
      "text": "1Q22 Organic Revenue: (2%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cf9aba1-1508-4a3b-bf9d-b6b8868b7ff3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.38,
        "x": 0.56,
        "y": 0.66
      },
      "kind": "metric",
      "text": "1Q22 Reported Revenue: (2%)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b44d729f-d0a6-4d33-9180-60381930b438",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.26,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure... 2. IQVIA NPA monthly.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3899cf66-8038-4468-9ae9-1145015921f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.18,
        "y": 0.05
      },
      "kind": "title",
      "text": "Salix 1Q22 Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e2dffe0-2dc3-485e-a30e-c352257e3e6e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "4b108160-99c4-4ce6-b512-a5b900104ef6",
      "evidence": "type: executive_summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 19,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7720718b-ea2d-4109-9564-eb09c0194463",
      "evidence": "Financial results and leverage discussion",
      "position": 0,
      "objective": "Highlighting the need for strategic alternatives",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}